Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5863

Sort by

Sort Order Select

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Estelle Bourbon, Maël Heiblig, Mathieu Gerfaud Valentin, Thomas Barba, Cécile-Audrey Durel, Jean Christophe Lega, Fiorenza Barraco, Pascal Sève, Yvan Jamilloux, Pierre Sujobert

Blood (2021) 137 (26): 3682–3684.

https://doi.org/10.1182/blood.2020010177

Published: 2021

Includes: Supplemental data

Journal Articles

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Blood (2021) 137 (11): 1527–1537.

https://doi.org/10.1182/blood.2020006923

Published: 2021

Includes: Supplemental data

Journal Articles

Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis

Emanuele Valeriani, Marcello Di Nisio, Nicoletta Riva, Omri Cohen, Juan-Carlos Garcia-Pagan, Marta Magaz, Ettore Porreca, Walter Ageno

Blood (2021) 137 (9): 1233–1240.

https://doi.org/10.1182/blood.2020006827

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Elise A. Chong, Bruce L. Levine, Stephan A. Grupp, Megan M. Davis, Don L. Siegel, Shannon L. Maude, Whitney L. Gladney, Noelle V. Frey, David L. Porter, Wei-Ting Hwang, Emeline R. Chong, Carl H. June, Stephen J. Schuster

Blood (2019) 134 (21): 1873–1875.

https://doi.org/10.1182/blood.2019002258

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

Kadriye Nehir Cosgun, PhD, Gauri Deb, MS, PhD, Xin Yang, MD, Gang Xiao, PhD, Teresa Sadras, PhD, Jaewoong Lee, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Lu Yang, PhD, Huimin Geng, PhD, John Chan, MD, Joo Y. Song, MD, Hassan Jumaa, PhD, Andrew G. Polson, PhD, Hans Clevers, MD PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 748.

https://doi.org/10.1182/blood-2019-127263

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 736.

https://doi.org/10.1182/blood-2019-124504

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia

Blood (2019) 134 (Supplement_1): 914.

https://doi.org/10.1182/blood-2019-129940

Published: 2019

Journal Articles

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Pietro Merli, MD, Annalisa Ruggeri, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Giulia Ceglie, MD, Katiana Gruppioni, MPH, Sanjeev Kommera, MS, Jenfue Maa, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 969.

https://doi.org/10.1182/blood-2019-123440

Published: 2019

Journal Articles

Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types

Susanna A Curtis, MD, Ariadna Forray, MD, Jeanne E. Hendrickson, MD, John D. Roberts, MD

Blood (2019) 134 (Supplement_1): 1028.

https://doi.org/10.1182/blood-2019-129106

Published: 2019

Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1272.

https://doi.org/10.1182/blood-2019-125773

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

NARROW

How I treat pediatric acute myeloid leukemia

CLL-IPI: valid in the era of oral inhibitors?

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis

The different flavors and splices of MCL

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only